Considering the beneficial effects of adenosine on cardiovascular function [110], ticagrelor could have pleiotropic effects beyond its platelet inhibitory effects, as treatment with ticagrelor reduced major cardiovascular adverse events (MACE) compared to clopidogrel, another P2Y12R antagonist that does not have impact on erythrocytes for purinergic activation, in patients with acute coronary syndrome [13]. The gene discussed is P2RY12; the disease is acute coronary syndrome.